SCHEMBL30592278

SCHEMBL30592278

CCCCCCCCCCCCCCCCC(=O)C1C(=O)OC(CO)C1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPSE Q9Y251 1/20 0.49
▸ PRKCA P17252 8/20 0.44
▸ PRKD3 O94806 1/20 0.43
▸ PRKCG P05129 1/20 0.43
▸ PRKCB P05771 1/20 0.43
▸ PRKCH P24723 1/20 0.43
▸ PRKCE Q02156 1/20 0.43
▸ PRKCQ Q04759 1/20 0.43
▸ PRKCD Q05655 1/20 0.43
▸ PRKD1 Q15139 1/20 0.43
▸ PTPN1 P18031 2/20 0.42
▸ CDC25B P30305 2/20 0.41
▸ TACR2 P21452 1/20 0.41
▸ CETP P11597 3/20 0.40
▸ CDC25A P30304 1/20 0.40
▸ DUSP3 P51452 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ DAGLA Q9Y4D2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22710203 0.75 BCHE (0.45) TACR2TSHR
SCHEMBL18080649 0.73 PDPK1 (0.44) TACR2ALDH1A1TSHR
SCHEMBL7774705 0.70 PTPN1 (0.45) HPSEPTPN1CDC25BMEN1KMT2A
SCHEMBL6296951 0.69 TACR2 (0.45) HPSEPTPN1TACR2ALDH1A1CYP3A4
SCHEMBL21679664 0.69 POLB (0.52) PRKCAPRKD3PRKCGPRKCBPRKCH
SCHEMBL21679680 0.69 POLB (0.52) PRKCAPRKD3PRKCGPRKCBPRKCH
SCHEMBL18456611 0.68 NAAA (0.46) TACR2ALDH1A1CYP3A4TSHRMAPK1
SCHEMBL18456612 0.68 NAAA (0.46) TACR2ALDH1A1CYP3A4TSHRMAPK1
SCHEMBL20741887 0.68 SLC6A2 (0.46) TACR2ALDH1A1TSHR
SCHEMBL1821071 0.68 CES2 (0.46) HPSEPTPN1CETPMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250204515-A1 Heparanase Inhibition for Graft Protection UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2025-06-26 — — US claimed
WO-2023175581-A1 HEPARANASE INHIBITION FOR GRAFT PROTECTION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-09-21 — — WO claimed
US-20250204515-A1 Heparanase Inhibition for Graft Protection UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2025-06-26 — — US disclosed
WO-2023175581-A1 HEPARANASE INHIBITION FOR GRAFT PROTECTION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250204515-A1 Heparanase Inhibition for Graft Protection HPSE, ENGASE, HPN HPSE 1/4885PRKCA 3985/4885PRKD3 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback